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A B S T R A C T
Methicillin-resistant Staphylococcus aureus (MRSA) infection continues to be a substantial global
problem with significant associated morbidity and mortality. This review summarises the discussions
that took place at the 4th MRSA Consensus Conference in relation to the current treatment options for
serious MRSA infections and how to optimise whichever therapy is embarked upon. It highlights the
many challenges faced by both the laboratory and clinicians in the diagnosis and treatment of MRSA
infections.
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1.1. Use of vancomycin
Vancomycin has been the drug of choice for treating severe
infections due to methicillin-resistant Staphylococcus aureus
(MRSA) during the last decades. Accumulating evidence of
increasing resistance, unachievable pharmacokinetic/pharmaco-
dynamic (PK/PD) targets and poorer outcomes challenges the
suitability of the prime place of vancomycin in treatment regimens
and guidelines [1–6].
Controversy still exists over the current, non-method-
dependent breakpoint of 2 mg/L, appreciating that if this were
to be lowered further the majority of isolates would be deemed
resistant [7]. A growing body of data showing significant
variability both in minimum inhibitory concentration (MIC)
measurements and accuracy of MIC determination demon-
strates the importance of the method of susceptibility testing
[8,9].
1.2. The vancomycin breakpoint
The most recent guidelines on the treatment of MRSA
published by the Infectious Diseases Society of America (IDSA)
in 2011 give no information on the importance of an MIC within
the susceptible range for clinical decision-making [10,11].
However, these were written in 2010 and evidence has
continued to emerge since their inception and subsequent
publication. Meta-analyses have consistently shown poorer
outcomes with MICs approaching the breakpoint (>1 mg/L),
including mainly episodes of bacteraemia but also pneumonia
and skin and soft-tissue infections (SSTIs) [12–14]. The
vancomycin MIC was significantly associated with mortality
for MRSA infection irrespective of the source of infection or MIC
methodology [odds ratio (OR) = 1.64, 95% confidence interval
1.14–2.37], although this was mostly attributable to blood-
stream infections and Etest MICs of 2 mg/L [12]. It is acknowl-
edged that the data used for these meta-analyses are
retrospective, that potential confounding factors were not
controlled and that the MIC was measured with different
techniques. To date, no randomised controlled studies have
been performed to address this question, but there are three
studies that have compared bacteraemic patients with infection
due to MRSA with a vancomycin MIC > 1 mg/L and treated with
daptomycin with a historical cohort of patients treated with
vancomycin [15–17]. These studies demonstrated that dapto-
mycin was superior to vancomycin in terms of clinical failure and
mortality rate. Notwithstanding the limited data, it is difficult to
ignore this message. For many, this is justification for lowering
the breakpoint once again [2], although not all data support the
association of MIC and worse outcome [18–21]. It is evident from
a clinical perspective that there are many variables influencing
the outcome of patients with S. aureus bacteraemia, including
age, co-morbidity, severity of infection (severe sepsis or shock)
and source of infection, but pharmacodynamic knowledge also
supports the concept that it is difficult to achieve the
pharmacodynamic target for vancomycin when the MIC is
>1 mg/L [22,23]. Arguably, if the breakpoint was to be lowered
to >1 mg/L, a significant proportion of isolates would become
resistant, limiting therapeutic options still further. A potential
solution would be to classify as intermediate those strains with a
MIC >1 mg/L and 2 mg/L, inducing clinicians to judge the best
option according to the clinical characteristics of the patients.
The severity of infection can therefore be given due consider-
ation.1.3. Methodology for determination of the vancomycin minimum
inhibitory concentration
There are limitations to the methodology for determining the
vancomycin MIC in the clinical setting where cost, efficiency and
clinically relevant turnaround times must be balanced appropri-
ately. The gold-standard broth microdilution (BMD) method is out
with the capacity for routine diagnostic use, thus commercial
vancomycin MIC detection methods are used in most clinical
diagnostic laboratories for susceptibility testing. Previously,
investigations evaluating the precision of automated testing
methods have used 1 log2 dilution from the reference method as
having essential agreement [8]. However, with a recent systematic
review and meta-analysis showing greater failure rates and mortality
with MICs of 1.5 mg/L or 2 mg/L (i.e. within 1 doubling dilution of the
current breakpoint), the discrimination between susceptible and less
susceptible isolates has become difficult and hence the precision of
automated systems has come under greater scrutiny [12].
Recent reports describe discrepancies in the ability of
automated systems to accurately determine the MIC of vancomy-
cin against MRSA compared with Etest or reference BMD methods
[8,24]. A recent study comparing four commercial MIC testing
systems (MicroScan, VITEK1 2, Phoenix and Etest) against the
Clinical and Laboratory Standards Institute (CSLI) reference BMD
method showed 61.8%, 54.3%, 66.2% and 36.7% absolute agreement
(0  dilution) with the BMD method, respectively [8]. Aside from the
precision in determination of MICs, this study also highlights the risk
of missing vancomycin MICs of 2 mg/L with certain automated
systems by undercalling resistance, especially when heteroresistant
vancomycin-intermediate S. aureus (hVISA) is involved [8]. Under-
calling of resistance occurs both with the VITEK1 2 and Phoenix
systems, although the reason for discrepancies in accuracy between
these systems is poorly understood, and given that these types of
system are in widespread use it urges for caution in interpretation of
susceptibility if infection is severe. Etest MIC determination, however,
is often known to produce values that are 1 dilution higher than BMD,
and this may prove a useful conservative estimate in evaluating
vancomycin MICs when treating serious MRSA infections [8,25,26].
The practical difficulties in determining an MIC have led some to
argue in favour of lowering the breakpoint as a pragmatic solution. If
MICs were determined by Etest, conventional breakpoints could be
retained, but the need for method-dependent breakpoints appears a
reasonable stance to adopt, with a breakpoint of >1.5 mg/L by Etest
and >1 mg/L by BMD.
1.4. Heteroresistance
hVISA is not associated with high mortality but with increased
failure rates, suggesting that resistance may have a fitness cost
[27–30]. According to this information, it would be interesting for
the clinical management of severe S. aureus bacteraemia treated
with vancomycin to know the presence of heteroresistance.
However, laboratory determination of heteroresistance is difficult,
with the gold-standard population analysis profiling being
impracticable in the routine diagnostic laboratory. In the context
of hVISA, teicoplanin antimicrobial sensitivity testing has been
postulated as better predictor of heteroresistance and a better
predictor of recurrence [31–33], but the literature is certainly far
from clear on the issue of teicoplanin [34,35].
Aside from difficulties in detecting hVISA, there is uncertainty
over the stability of resistance determinants, making the
interpretation of techniques even more complex [36–38]. Most
VISA appear to be unstable and lose this phenotype in the absence
of selective pressure [39,40]. Currently, whether VISA and hVISA
are absolute states or an expression of variability is unknown [41].
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phisms and the expression of these, are another key area for
ongoing research [42–45]. Until these mechanisms are more fully
understood, current practice will consist of somewhat unsatisfac-
tory phenotypic methods of resistance detection before molecular
methods of resistance detection or certainty of susceptibility
become available [28].
1.5. Vancomycin pharmacokinetic/pharmacodynamic data
1.5.1. Dosing
It is widely accepted that the ratio of the area under the
concentration–time curve (AUC) to MIC (AUC/MIC) is the best
pharmacodynamic predictor of vancomycin efficacy, and a value
400 is associated with higher success rates in patients with
respiratory tract infections [46] and bacteraemia [5] and 600 in
patients with septic shock [47]. These data support the recent
guidelines for vancomycin dosing [22] that recommend a trough
serum concentration of 15 mg/L, supported by clinical data [48].
According to Monte Carlo simulation, this target is attainable only
when the MIC of MRSA is 1 mg/L [23]. The recommended daily
dose in order to attain the target is 15–20 mg/kg every 8–12 h if the
patient has normal renal function [22]. A 25–30 mg/kg loading
dose is recommended for critically ill patients. However, increased
clearance and the need for haemofiltration, both common in
critically ill patients, are associated with low serum concentrations
[49–52] and difficulty in early achievement of the target.
To improve the efficacy of vancomycin, some authors propose
administration by continuous infusion (CI). According to animal
and clinical data, the AUC/MIC ratio is the best pharmacodynamic
predictor of vancomycin efficacy; however, its bactericidal
activity is time-dependent. Therefore, its administration by CI
would be a reasonable mode of administration. CI of vancomycin
in a pig lung model showed evidence for increased efficacy [53],
but clinical experience is limited [54,55]. A clinical trial in
intensive care unit (ICU) patients did not show better outcome
using CI but it was associated with an earlier achievement of
desired trough concentrations, and concentrations were more
stable over time [56]. In addition, a meta-analysis showed
decreased nephrotoxicity with CI [57]; however, patients
included in some of the articles were outpatients and so with a
lower risk of developing nephrotoxicity. A recent article including
a large cohort of ICU patients receiving vancomycin by CI showed
a rate of nephrotoxicity of 24%, where the mean concentration of
vancomycin within the first 3 days and the duration of treatment
were independently associated with a higher risk of nephrotoxi-
city [58]. These data suggest that CI could be a potential
administration mode for severe infections, but close monitoring
of serum concentration and renal function is mandatory, most
especially for patients with risk factors for nephrotoxicity (i.e.
concomitant nephrotoxic drugs). There is no clinical experience
using CI when the MIC is >1 mg/L but the expected AUC with a
plateau of 20–25 mg/L is 480–600 mg h/L. For an MIC of 1.5–
2 mg/L the ratio would be 240–400, therefore below the required
target to achieve a high success rate [59]. An experimental
endocarditis model showed a high sterilisation rate using CI at
20 mg/L for MRSA with an MIC of 1 mg/L but a high failure rate
and selection of strains with higher MICs using both 20 mg/L or
40 mg/L plateaus for infections due to MRSA strains with MICs of
2 mg/L and 8 mg/L, respectively [60]. According to this informa-
tion, for infections due to strains with an MIC > 1 mg/L it would
be better to use an alternative antibiotic, particularly in severe
infections.
Beyond the serum concentrations, it is known that vancomycin
diffusion to some areas is low. For instance, concentrations in
epithelial lining fluid [61] and in soft tissue of diabetic patients arelow [62]. Taking into account the good diffusion of linezolid to
poorly vascularised tissues, this difference could explain the
superiority of linezolid over vancomycin in SSTIs in patients with
vascular insufficiency described in a subanalysis of a previous
randomised study [63]. These data suggest that in these clinical
situations the vancomycin dose should be higher in order to
achieve acceptable success rates.
Promoting higher doses promotes accepting nephrotoxicity,
which requires an assessment of the level of concern and
appropriate risk assessment [57]. An established link exists
between vancomycin levels and renal toxicity, with van Hal
et al. among others showing that if the vancomycin trough is
>20 mg/L toxicity is 33%, and if it is <20 mg/L then toxicity is 20%,
so levels ought to be measured [28,64]. A recent meta-analysis by
van Hal et al. showed an increased probability of a nephrotoxic
event not only with increasing trough concentrations but also
length of exposure [28].
It is important that pharmacists advise clinicians if they are
going to change from branded products to generics, or in the case of
vancomycin between different generics. The World Health
Organization (WHO) and drug regulatory agencies consider
products for parental use a therapeutically equivalent if they are
pharmaceutically equivalent [65]. Data showing significant
differences in therapeutic equivalence in a neutropenic mouse
model have previously caused concern [66]. However, a more
recent study using a rabbit endocarditis model did not demon-
strate any significant differences between different vancomycin
generics, including those commonly used in the USA and Western
Europe [67]. Where pharmaceutical parameters of equivalence
allow for a range of 80–125% of the generic drug in serum
concentrations compared with the branded drug, this has potential
important consequences for antimicrobials such as vancomycin
where MIC data suggest the need for doses approaching levels
associated with increased toxicity [65].
2. Linezolid
2.1. Linezolid pharmacokinetics/pharmacodynamics
2.1.1. Special situations
2.1.1.1. Obesity. Data exist that support no need for increased
dosing in patients weighing up to 150 kg [68]. However, in obese
patients, observed serum levels have been lower than in the non-
obese population, with one case report of a patient with a body
mass index (BMI) of 37 describing clinical failure because of
reduced serum concentration trough levels below the MIC90 (MIC
for 90% of the isolates) [69]. This suggests that there may be a need
for increasing the dose in morbidly obese patients or in those >50%
of their calculated ideal body weight [69–71].
2.1.1.2. Critically ill patients. A linezolid trough <2 mg/L was found
in 29% of patients with sepsis [72], which was independently
associated with an estimated glomerular filtration >80 mL/min,
typically found in patients with severe sepsis or septic shock [49].
The authors recommend a loading dose of 600 mg three times daily
for the first 24 h, or the administration of the total daily dose by CI.
Indeed, linezolid is stable and recent data demonstrated that
1200 mg/24 h by CI maintained concentrations between 7 and
10 mg/L and was associated with better pharmacodynamic
parameters than intermittent administration of the same daily
dose [73].
Administration of 1200 mg by CI led to a steady-state
concentration in epithelial lining fluid of 7 mg/L [74], in
agreement with a diffusion rate of linezolid of >90%. Among
critically ill patients, the need of extracorporeal membrane
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in two of three patients, therefore when treating strains with an
MIC of 2–4 mg/L the authors recommended either a loading
dose or CI [75].
2.1.1.3. Concomitant use of rifampicin. The combination of linezolid
and rifampicin is an attractive oral alternative in foreign-body
infections; however, two studies performed in healthy volunteers
have analysed this interaction and both articles showed a
reduction of ca. 30% in the AUC of linezolid [76,77]. In addition,
two cases of orthopaedic implant infections treated with this
combination had a low linezolid serum concentration that was
associated with clinical failure [78]. This is possibly explained
because rifampicin induces P-glycoprotein, a transporter that
increases the clearance of linezolid [79].
2.1.1.4. Prolonged use of linezolid. For the treatment of implant
infections or tuberculosis it is necessary to prolong the adminis-
tration of linezolid. Some data suggest that linezolid inhibits its
own metabolism [80], therefore prolonged treatment is associated
with a progressive increase in serum concentrations that are
associated with haematological toxicity [81,82]. The linezolid toxic
trough is not well defined but supposedly should not be >8 mg/L
(ideally 2–7 mg/L), and therapeutic drug monitoring (TDM) should
probably be performed in certain circumstances [79,81]. A recent
study analysed the trough concentrations in consecutive patients
and found a mean trough of 9 mg/L in patients who developed
haematological toxicity compared with 4 mg/L in those without
toxicity [82].
2.1.1.5. Renal failure. Although linezolid requires no dose adjust-
ment in renal failure, haematological toxicity was more frequent in
patients with end-stage renal disease than in those with non-end-
stage renal disease [83,84], and in a general population with sepsis
a creatinine clearance of <50 mL/min was an independent
predictor of thrombocytopenia [85]. It would be reasonable that
linezolid clearance is decreased in patients with low glomerular
filtration. Tsuji et al. [86] showed that the linezolid concentration
was significantly higher than the predicted concentration in three
patients with glomerular filtration <40 mL/min, and severe
thrombocytopenia developed as the linezolid concentration
increased. These findings have recently been confirmed in a study
that included 30 patients [87]. Thrombocytopenia occurred in 17
patients (56.7%) and the median linezolid trough concentrations
on Day 3 were significantly higher in patients with renal
impairment than in patients without renal impairment
(14.7 mg/L vs. 4.8 mg/L; P = 0.0001). Development of thrombocy-
topenia occurred significantly more frequently in patients with a
linezolid trough concentration >7.5 mg/L (OR = 90.0; P = 0.0001)
and renal impairment (OR = 39.0; P = 0.0002). These data suggest
the need for close monitoring in these patients and to consider
TDM.
2.2. Comparative studies with linezolid
Extracted patients from a phase 4 clinical trial of oral linezolid
versus intravenous (i.v.) vancomycin with ischaemic/vascular
problems showed that linezolid was better than vancomycin,
with an OR of 4, probably due to better diffusion of linezolid to
poorly vascularised tissues [63,88].
In a randomised study, linezolid has demonstrated a higher
success rate than vancomycin in nosocomial pneumonia due to
MRSA (ZEPHyR study); however, mortality was similar in both
arms and some authors criticised the vancomycin dosage [89–91],
therefore there is still a debate in the literature about the first-line
agent for MRSA pneumonia [92,93].3. Daptomycin
3.1. Daptomycin pharmacokinetics/pharmacodynamics
The authors suggest a high dose of daptomycin (8–10 mg/kg)
irrespective of the source of bacteraemia for the initial three doses
[94]. If the infection is subsequently found to be uncomplicated,
the dosage can then be reduced. A hard-hitting approach is
recommended empirically. Although eosinophilic pneumonia has
been reported, this appears to be rare and idiosyncratic.
3.2. Combination therapy with daptomycin
Limited, though accumulating, data exist for the use of
combination therapy with daptomycin, including both animal
models and in vitro data. Most available data exist on combination
therapy with daptomycin and b-lactam antibiotics [95,96].
Oxacillin, in particular, appears to be very efficacious [97,98]. b-
Lactams improve the binding of daptomycin by increasing the net
negative charge of the cell membrane [96]. This may prevent the
development of daptomycin resistance [96]. A recent article
suggests that this benefit is particular for those b-lactams that bind
to penicillin binding protein-1 (PBP1) [99].
Good data exist for the combination of daptomycin and
trimethoprim/sulfamethoxazole, with recent case reports on the
treatment of a Staphylococcus epidermidis meningitis and an MRSA
complicated endocarditis [100,101]. Two cases of vertebral
osteomyelitis reported by Avery et al. also show this combination
favourably for isolates that are daptomycin-non-susceptible and
vancomycin-intermediate [102].
High-dose daptomycin and fosfomycin have been used
successfully in endocarditis, even for daptomycin-non-susceptible
isolates [103,104]. Unfortunately, problems associated with i.v.
fosfomycin supply in some European countries could render this
option impractical.
Daptomycin and rifampicin is a good combination for infection
involving prosthetic devices [105]. There are conflicting results in
experimental models [106,107] but recent clinical data in severe
staphylococcal infections reported good results with this combi-
nation [108]. Interestingly, the authors found a good correlation
between results of synergy using the chequerboard method and
clinical outcome but not with killing curves. The combination has
been recently retrospectively reviewed in 16 patients with
orthopaedic infection with a success rate of 94% [109].
Combination therapy avoids the development of resistance to
daptomycin [110]. Combination therapy should therefore have
potential in patients with endocarditis, undrainable abscesses and
other high-inoculum infections. Knowing that daptomycin with
oxacillin increases bactericidal activity and decreases the devel-
opment of resistance [97] leads to speculation regarding potential
advantages in empirical combination therapy.
4. Anti-MRSA cephalosporins
4.1. Ceftaroline
No new PK/PD data and no new clinical studies are available
since the last consensus meeting in 2012. There have, however,
been in vitro comparisons of ceftaroline versus linezolid,
vancomycin and daptomycin showing equivalent efficacy where
the ceftaroline MIC is 2 mg/L [111], and a study showing a
potential role in isolates with reduced susceptibility to linezolid,
daptomycin or vancomycin [112]. Data demonstrating adequate
lung penetration [113] and also a case involving the clinical use of
ceftaroline have been described [114].
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to achieve at least 50% concentration higher than the MIC [115].
Ceftaroline epithelial lining fluid concentrations in a murine model
were similar to serum concentrations, and exposures simulating
human doses of 600 mg twice daily achieved recommended
pharmacodynamic targets [113]. Isolates with an MIC > 1 mg/L
may require a dose increase, but there are no data to support this.
Dosing at 600 mg twice daily for SSTI appears reasonable, but the
authors believe that in community-acquired pneumonia (CAP)
dosing may not be high enough. Unfortunately there already exist
Greek strains resistant to ceftaroline, so we can expect more strains
to develop resistance [116]. The manufacturer may wish to look at
higher dosing or modify the mode of administration, for instance,
prolonged infusion, to combat/overcome this [117].
Being a b-lactam, ceftaroline has benefits in terms of decreased
toxicity with good efficacy. There are, however, no clinical data on
isolates with an MIC > 2 mg/L. However, consideration still needs
to be given to the exact clinical niche that ceftaroline will fill. There
is some evidence to suggest that it may fulfil a role where there is
reduced susceptibility to vancomycin, daptomycin or linezolid
[112]. There is good experience in a few cases of bacteraemia, with
one case of endocarditis showing sterility of vegetations at 13 days
of therapy [114]. Ceftaroline has lower MICs than ceftriaxone for
Streptococcus pneumoniae [118], but also offers broad-spectrum
cover so could be used for Gram-negative infections. Ceftaroline
has shown similar activity to ceftazidime for some Enterobacter-
iaceae [119]. The problem is that ceftaroline has the same
pharmacokinetics as ceftazidime but we administer 2 g/8 h of
ceftazidime and only 600 mg/12 h of ceftaroline.
Ceftobiprole has a promising role in the treatment of hospital-
acquired pneumonia. With efficacy similar to ceftazidime and
cefepime against Pseudomonas spp., this would be a useful drug in
the ventilator-associated pneumonia (VAP) subset [120]. However,
at current dosing, conflicting data exist for the support of
ceftobiprole use in VAP. Suggestions that ceftobiprole is unlikely
to meet the desired pharmacodynamic targets when pharmacoki-
netic parameters are altered have been countered by Monte Carlo
simulation based on phase 1 studies showing that target
attainment is likely to be achieved, even in severely ill patients
[121,122]. There needs to be a re-assessment of the quality of data
for ceftobiprole use in SSTI, however the pneumonia data were of
good quality. Ceftobiprole was recently shown to be non-inferior to
linezolid and ceftriaxone for treating CAP [123].
5. New oxazolidinones
Tedizolid is currently only approved for SSTIs. However, it has
demonstrated efficacy against wild-type and drug-resistant
pathogens, including linezolid-resistant S. aureus strains with
mutations both in chromosomal genes and ribosomal proteins
[124].
6. Conclusions
Despite significant developments in the management and
treatment of MRSA infection, many questions remain unanswered
and the practical means to find solutions is challenging.
Fundamental problems such as accurate determination of the
MIC to the first-line antimicrobial agent are becoming apparent, as
is the need to acknowledge the mode of susceptibility testing used.
In the absence of a precise laboratory method that can predict the
efficacy of vancomycin, it is understandable that newer agents will
find favour over glycopeptides, particularly in severe infections
where margins for error are narrow. Optimising all current
therapies by dosing appropriately, and in certain circumstances
considering combination therapy, will increase the efficacy of theantibiotics to hand and may lessen the potential for developing
resistance.
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